Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance
Combined glucose-lowering therapy, comprising of basal insulin with glucagon-like peptide-1 (GLP-1) analogues, has become central to the treatment of type 2 diabetes both at the start of insulin therapy, and as an alternative to basal-bolus insulin. The combination of insulin detemir (insulin analog...
Guardado en:
Autores principales: | Lyudmila Alexandrovna Ruyatkina, Maxim Sorokin |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3e6b1c403d2245b08a42415262fb3420 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Detemir potential applications in the treatment of diabetes during pregnancy: proven benefits and perspectives
por: Lyudmila A. Ruyatkina, et al.
Publicado: (2016) -
Prospective study of efficacy and safety of insulin pump therapy in children and adolescents
por: Andrey Olegovich Emel'yanov, et al.
Publicado: (2010) -
First GLP-1 analog liraglutide: the result of clinical trails on efficacy
por: Alexander Sergeevich Ametov, et al.
Publicado: (2011) -
Can simple intensification of therapy with modern two-phase insulin help in type 2 diabetes when target glycemia failed to be achieved withbasal insulin? Results of subanalysis in the PRESENT study
por: Ch S Yang, et al.
Publicado: (2009) -
New strategies of insulin therapy - a way to effective glycemic control of type 2 diabetes mellitus
por: Elena Valer'evna Biryukova
Publicado: (2009)